Molecular Cancer Therapeutics : Impact Factor & More
eISSN: 1538-8514pISSN: 1535-7163
Share this on:
Key Metrics
CiteScore 
10.2
H-Index
190
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.21
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Molecular Cancer Therapeutics
Molecular Cancer Therapeutics Journal Specifications
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Monthly |
| General Details |
View less
Planning to publish in Molecular Cancer Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Molecular Cancer Therapeutics
Distinct H3K27 Methylation States Drive Cellular Responses to the Histone Demethylase Inhibitor GSK-J4 in Ovarian Cancer Cells.
- 27 Apr 2026
- Molecular cancer therapeutics
MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells.
- 27 Apr 2026
- Molecular cancer therapeutics
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
- 22 Apr 2026
- Molecular cancer therapeutics
QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models.
- 22 Apr 2026
- Molecular cancer therapeutics
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.
- 21 Apr 2026
- Molecular cancer therapeutics
CerS2 is a druggable target in triple-negative breast cancer.
- 21 Apr 2026
- Molecular cancer therapeutics
Distinct H3K27 Methylation States Drive Cellular Responses to the Histone Demethylase Inhibitor GSK-J4 in Ovarian Cancer Cells.
- 27 Apr 2026
- Molecular cancer therapeutics
MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells.
- 27 Apr 2026
- Molecular cancer therapeutics
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
- 22 Apr 2026
- Molecular cancer therapeutics
QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models.
- 22 Apr 2026
- Molecular cancer therapeutics
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.
- 21 Apr 2026
- Molecular cancer therapeutics
CerS2 is a druggable target in triple-negative breast cancer.
- 21 Apr 2026
- Molecular cancer therapeutics
FAQs on Molecular Cancer Therapeutics
How long has Molecular Cancer Therapeutics been actively publishing? 
What is the publishing frequency of Molecular Cancer Therapeutics?
How many articles did Molecular Cancer Therapeutics publish last year?
What is the eISSN & pISSN for Molecular Cancer Therapeutics?
What is Citescore for Molecular Cancer Therapeutics?
What is the H Index for Molecular Cancer Therapeutics ?
What is SNIP score for Molecular Cancer Therapeutics?
What is the SJR for Molecular Cancer Therapeutics?
Who is the publisher of Molecular Cancer Therapeutics?
